On July 17th, Motherboard—Vice.com’s channel devoted to technologies, cultures, and discoveries that are reshaping our world-—spotlighted the growing momentum around the Targeting Aging with Metformin (TAME) trial led by AFAR Deputy Scientific Director and two-time grantee Nir Barzilai, M.D.
The goal of the project is to implement a clinical study testing metformin, an FDA approved drug that researchers’ believe may have the ability to postpone the onset of chronic diseases associated with aging.
The article chronicles an unprecedented meeting on June 24 between Barzilai’s team and the FDA to build the case to get aging approved as an “indication”—a condition that calls for a specific medical treatment—and thus a drug target.
"Our aim is to increase the healthspan of elderly people in order to increase our quality of life, and help lighten the economic burden that healthcare represents," Barzilai notes.
AFAR has helped support the TAME planning process.
Read the complete article here.
Nir Barzilai, MD, is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and a two-time AFAR grant recipient.
For more insight into pipeline drugs that researchers believe may have to ability to postpone age-related conditions, check out these related news stories featuring AFAR experts in the Wall Street Journal and Bloomberg News.
